N-(5-(2-(benzyl(2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)butyl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide | 1361398-75-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(5-(2-(benzyl(2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)butyl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide
• CAS: 1361398-75-5
• 化学式: C₄₃H₅₀N₄O₆
• 分子量: 718.893
• InChiKey: UPTITVCBUDDJIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.22
• 重原子数：
  53.0
• 可旋转键数：
  18.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  112.93
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  N-(5-(2-(benzyl(2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)butyl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 以80%的产率得到N-(5-(2-((2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)butyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)formamide
  参考文献：
  名称：

  Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD

  摘要：

  We designed and synthesized a novel class of dual pharmacology bronchodilators targeting both beta 2-adrenoceptor and PDE4 by applying a multivalent approach. The most potent dual pharmacology molecule, compound 29, possessed good inhibitory activity on PDE4B2 (IC50 = 0.278 mu M, which was more potent than phthalazinone, IC50 = 0.520 mu M) and possessed excellent relaxant effects on tracheal rings precontracted by histamine (pEC(50) = 9.3). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.013
• 作为产物：
  描述：

  2-(2-bromobutyl)-4-(3,4-dimethoxyphenyl)-4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one 反应 7.0h， 生成 N-(5-(2-(benzyl(2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)butyl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide
  参考文献：
  名称：

  Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD

  摘要：

  We designed and synthesized a novel class of dual pharmacology bronchodilators targeting both beta 2-adrenoceptor and PDE4 by applying a multivalent approach. The most potent dual pharmacology molecule, compound 29, possessed good inhibitory activity on PDE4B2 (IC50 = 0.278 mu M, which was more potent than phthalazinone, IC50 = 0.520 mu M) and possessed excellent relaxant effects on tracheal rings precontracted by histamine (pEC(50) = 9.3). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.013